Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06536452
- Status
- Recruiting
Conditions
- Chronic Lymphocytic Leukemia
- Monoclonal B-Cell Lymphocytosis
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Non-Interventional Study — OTHERNon-interventional study
Study Details
This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.
Key Dates
- Start date
- Nov 18, 2016
- Status verified
- Mar 2026
- Primary completion
- Nov 18, 2028
- Completion
- Nov 18, 2028
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: ObservationalPatients undergo blood sample collection and bone marrow aspiration and biopsy and have their medical records reviewed on study.
Primary Outcome Measure
Effects of MBL on bone marrow function [ Time Frame: Baseline ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Neil E. Kay, M.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Family Study of Lymphoproliferative DisordersRecruiting · Mayo Clinic · Rochester, Minnesota
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPHASE2 · Recruiting · Mayo Clinic · Scottsdale, Arizona
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)PHASE1 · Recruiting · Imugene Limited · Gilbert, Arizona